trending Market Intelligence /marketintelligence/en/news-insights/trending/rcbh77d64bqp5jpmqme9mw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

MabVax schedules reverse stock split with hopes to regain Nasdaq compliance

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


MabVax schedules reverse stock split with hopes to regain Nasdaq compliance

San Diego-based MabVax Therapeutics Holdings Inc. has scheduled its previously announced 1-to-3 reverse stock split for Feb. 16.

With the stock split, the biotech company hopes to regain compliance with Nasdaq's listing rule that requires a $1.00 minimum closing bid price for at least 10 trading days.

MabVax has until March 5 to regain compliance with the stock market.

The company previously regained compliance with Nasdaq's minimum equity requirement in November 2017.